Log In
BCIQ
Print this Print this
 

Herpes simplex virus type 2 (HSV-2) vaccine, Vaxfectin-formulated plasmid DNA HSV-2 vaccine (VCL-HB01)

  Manage Alerts
Collapse Summary General Information
Company Vical Inc.
DescriptionTherapeutic plasmid DNA vaccine encoding the herpes simplex virus type 2 (HSV-2) glycoprotein D and tegument protein VP11/12 (UL46) formulated with Vaxfectin lipid adjuvant
Molecular Target Not applicable
Mechanism of ActionVaccine
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationHerpes simplex virus (HSV)
Indication DetailsVaccinate against herpes simplex virus type 2 (HSV-2) infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today